PrimeVax Immuno-Oncology

Focus: PrimeVax Immuno-Oncology is a newly founded (2024) biotechnology company developing novel immunotherapies combining dengue virus vectors with autologous dendritic cells for oncology and infectious disease indications. The company is in early-stage development with a focused pipeline targeting melanoma.

Oncology Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About PrimeVax Immuno-Oncology

AI assessmentNot Hiring

No open roles listed right now. Follow PrimeVax Immuno-Oncology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Dengue Virus-1 #45AZ5

Advanced Melanoma

Phase 1

Clinical Trials (1)

NCT03989895Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma

Phase 1

Help build intelligence for PrimeVax Immuno-Oncology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly founded company (2024) with a novel dual-modality platform combining viral vectors and cell therapy in immuno-oncology
Focus on underexplored therapeutic approach (dengue virus + dendritic cells) with potential first-mover advantage in a high-value oncology space
Early-stage startup environment offers accelerated career progression and broad impact potential for founding team members

Watch Out For

Zero current job openings and no visible hiring activity signal company is in stealth/early funding phase with limited near-term career entry points
Pre-revenue stage with undisclosed funding and no clarity on financial runway, cash position, or Series A timeline creates employment stability uncertainty
Extremely early pipeline (3 Phase 1 trials only, no Phase 2 or Phase 3 programs) means multi-year de-risking period before meaningful clinical validation or inflection points

Generated by Claude from PrimeVax Immuno-Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PV-001-DC

Metastatic Melanoma

Phase 1

Clinical Trials (1)

NCT03803397Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma

Phase 1

Dengue Virus-1 #45AZ5

Advanced Melanoma

Phase 1

Clinical Trials (1)

NCT03990493Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 3 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

3 pipeline

Marketed

Pipeline